Cardiometabolic & kidney

Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease

N Engl J MedPublished multinational, double-blind, randomized, placebo-controlled trial

Primary result · 3-point MACE (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke)Result — go to the resultHazard ratio 0.99 95% CI 0.88–1.11

Authors' conclusion

Among patients with atherosclerotic cardiovascular disease, chronic kidney disease, and cardiovascular inflammation, a strategy of lowering interleukin-6 levels with ziltivekimab did not result in a lower risk of cardiovascular events than placebo. (Funded by Novo Nordisk; ZEUS ClinicalTrials.gov number, NCT05021835.).

Study context

Population
Adults with established atherosclerotic cardiovascular disease, chronic kidney disease, and cardiovascular inflammation (high-sensitivity CRP level of ≥2 mg per liter)
Participants
6,376 adults
Comparison
Ziltivekimab vs placebo
  • Ziltivekimabn = 3,184
  • Placebon = 3,192reference
Primary endpoint
3-point major adverse cardiovascular event (MACE):
  • Death from cardiovascular causes
  • Nonfatal myocardial infarction
  • Nonfatal stroke
Follow-up
Median 33 months
Methodological details1:1 randomization
  • 1:1 randomization

Primary result

As reported in the abstract

3-point MACE (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke)

Hazard ratio

0.99

95% CI 0.88–1.11

P = 0.84

Events by treatment group

Ziltivekimabvs placebo
HR 0.99 (95% CI 0.88–1.11); P = 0.84

Further findings

OutcomeEstimate
Between-group difference in median percent change in inflammatory biomarkers · 24 monthsZiltivekimab vs placebodifference in median percent change, free interleukin-6 −76 percentage points
Between-group difference in median percent change in inflammatory biomarkers · 24 monthsZiltivekimab vs placebodifference in median percent change, high-sensitivity CRP −64 percentage points

Baseline characteristics

Mean age
69.4 years
Women
27.5%

Safety

Serious adverse events

Serious infections

Original publication

Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease. N Engl J Med. Published 7 November 2026. doi:10.1056/nejmoa2612126

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.